Very Rare Cancer Consortium Tumor Board Meeting

September 17, 2020, 4:00pm – 6:00pm | New York Genome Center

Please join us for the Very Rare Cancer Consortium Tumor Board Meeting. This new initiative aims to bring cancer researchers across New York to the table to discuss compelling rare cancer cases presented by physicians and scientists from the New York Genome Center’s partner institutions. Click here to learn more about the Very Rare Cancer Consortium.

Thursday, September 17, 2020
4pm – 6pm


Case Conference 
This will be a VIRTUAL meeting via Zoom.
Please note registration is required.

Anal cancer is a rare disease with limited therapeutic options. The majority of cases are caused by HPV infection. In recent years clinicians have noted an increase in anal cancer among people with HIV in the greater NYC area. Patients with HIV have a substantial risk of aggressive high-grade anal cancer precursors and may also have worse outcomes from anal cancer. This raises questions about the role of HIV in the natural history of this poorly understood cancer and possible carcinogenic and prognostic synergies in HIV and HPV co-infection. We will hear from experts from different areas in these studies and discuss potential collaborations through the VRCC.



Kevin Du, MD, PhD, MSCI
Associate Professor
Residency Program Director
Department of Radiation Oncology
NYU Langone Medical Center
“Disease Overview”


Paz Polak, PhD
Assistant Professor
Department of Oncological Sciences
Icahn School of Medicine at Mount Sinai 


Keith Sigel, MD, PhD, MPH
Associate Professor of Medicine
Division of General Internal Medicine
Division of Infectious Diseases
Icahn School of Medicine at Mount Sinai
“Persistent HPV16 and Multifocal Recurrent Carcinoma in Situ in a Person with HIV,  As Part of an Ethnically Diverse Cohort of Precancer Patients”
(Copresented with Paz Polak, PhD)


David P. Horowitz, MD
Assistant Professor of Radiation Oncology
NewYork-Presbyterian/Columbia University Irving Medical Center
“47-Year-Old Woman with Kidney Transplant and History of Vulvar Intraepithelial Neoplasia Who Develops Anal Cancer While On Surveillance for Gynecological Malignancy”


Michael Buckstein, MD, PhD
Associate Professor
and Residency Program Director
Department of Radiation Oncology
Icahn School of Medicine at Mount Sinai
A 41-Year-old Male with HIV, HSIL, and a Buschke-Lowenstein Tumor of the Anus”


Paul Romesser, MD
Assistant Attending
Early Drug Development Service,
Department of Medicine
Gastrointestinal Service, Department of
Radiation Oncology
Memorial Sloan Kettering Cancer Center


Salma Jabbour, MD
Professor, Vice Chair of Clinical Research
& Faculty Development
Department of Radiation Oncology
Rutgers Cancer Institute of New Jersey
“57-Year-Old Woman with Synchronous Anal and Cervical Squamous Cell Carcinomas”

“71-Year-Old Man Who Developed Lung Squamous Cell Carcinoma Years After Anal Squamous Cell Carcinoma”
(Copresented with Paul Romesser, MD)


Timothy Wilkin, MD, MPH
Professor of Medicine, Division of
Infectious Diseases
Assistant Dean, Clinical
Research Compliance
Institutional Official for
Human Research Protections
Weill Cornell Medicine/NewYork-Presbyterian
“Man Living with HIV Develops Anal Cancer During Extended Observation of Anal High Grade SIL”


Any questions on this event, contact